Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
Arcus Capital Partners LLC grew its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 31.7% during the fourth quarter, ...
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Marcus Stroman got his 2025 Spring Training with the New York Yankees back on track. The controversial right-hander was at ...
Another sign, called tendon xanthomata, leads to swelling in areas like your knuckles, the back of your ankle, and the ...
The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback